Showing 61-70 of 354 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| The KQ1 serum study: amendment & extension | University of Miami | Dirk Homann | Cures | 01-April-2025 to 31-October-2027 | $1.723.254,07 |
| Towards an integrated proteomic and transcriptomic single-cell atlas of the human pancreas | University of Miami | Dirk Homann | Cures | 01-April-2025 to 31-March-2027 | $53.972,92 |
| Nano-encapsulated microparticulate drug delivery platforms for decreasing islet graft immunogenicity | University of Miami | Dhanashree Surve | Cures | 01-March-2026 to 28-February-2029 | $274.010,00 |
| Localized delivery of costimulatory inhibitors and tolerogenic stromal cells for targeted immunomodulation in beta cell replacement | University of Miami | Alice Tomei | Cures | 01-February-2024 to 31-January-2027 | $824.892,00 |
| Artificial Intelligence-driven redesign of beta cell regulatory logic for resilience to inflammation | University of Massachusetts Medical School | Rene Maehr | Cures | 01-April-2026 to 31-March-2027 | $199.999,88 |
| In vivo interactions and trafficking of islet antigen-specific human effector T cells and Tregs | University of Massachusetts Medical School | Michael Brehm | Cures | 01-November-2024 to 31-October-2027 | $825.000,00 |
| Interrogation of FBR immunity using novel humanized mice | University of Massachusetts Medical School | Michael Brehm | Cures | 01-October-2026 to 30-September-2027 | $300.000,00 |
| A Cure for Type 1 Diabetes | University of Massachusetts Medical School | David Harlan | Cures | 01-October-2025 to 30-September-2029 | $16.000.000,00 |
| Defining the target product profile of intra-lymph node depots as a durable antigen-specific immunotherapy for T1D | University of Maryland | Christopher Jewell | Cures | 01-April-2026 to 31-March-2029 | $1.199.997,36 |
| Determining how NKG2D signaling drives autoimmune diabetes | University of Kansas Medical Center Research Institute, Inc. | Mary Markiewicz | Cures | 01-September-2023 to 31-August-2026 | $750.000,00 |